Latest News

FDA Approves Midostaurin for Acute Myeloid Leukemia

FDA Approves Midostaurin for Acute Myeloid Leukemia

The FDA approved midostaurin for patients with newly diagnosed, FLT3 mutation-positive acute myeloid leukemia.

FDA Approves Brigatinib for ALK+ NSCLC After Crizotinib

FDA Approves Brigatinib for ALK+ NSCLC After Crizotinib

The FDA has approved brigatinib, a dual ALK and EGFR inhibitor, for the treatment of patients with ALK-positive NSCLC who progressed while receiving or are intolerant to crizotinib.

Characterizing Therapy-persistent Leukemic Stem Cells in CML

Characterizing Therapy-persistent Leukemic Stem Cells in CML

There is high heterogeneity among therapy-persistent LSCs with differences in response to TKI therapy among patients with newly diagnosed CML.

Complex Karyotype, TP53 Mutations Associated With HCT Outcomes in Myelodysplasia

Complex Karyotype, TP53 Mutations Associated With HCT Outcomes in Myelodysplasia

Based on the results of this study, an alternative to HCT should be considered for patients with CK and mutations in TP53 or the RAS pathway.

USPSTF Releases Study Proposal for Pancreatic Cancer Screening

USPSTF Releases Study Proposal for Pancreatic Cancer Screening

The US Preventative Services Task Force released a proposed plan for conducting a systematic review of pancreatic cancer screening.

FDA Approves Regorafenib for Second-line in Hepatocellular Carcinoma

FDA Approves Regorafenib for Second-line in Hepatocellular Carcinoma

Regorafenib, a multikinase inhibitor, was approved by the FDA for the treatment of hepatocellular carcinoma after prior sorafenib therapy.

Neoadjuvant Chemotherapy Followed by Surgery for Metastatic Gastric Cancer

Neoadjuvant Chemotherapy Followed by Surgery for Metastatic Gastric Cancer

Neoadjuvant FLOT followed by surgery improves outcomes among patients with gastric or gastroesophageal junction cancer.

African Americans at Higher Risk of Metastatic Prostate Cancer

African Americans at Higher Risk of Metastatic Prostate Cancer

African American men have a higher incidence of preclinical prostate cancer and are more likely to progress to metastatic disease.

Chromosome Instability Associated With Death in NSCLC

Chromosome Instability Associated With Death in NSCLC

Chromosome instability was associated with an increased risk of recurrence and mortality among patients with early-stage NSCLC.

miRNA Repression May Drive Aberrant Signaling in MM

miRNA Repression May Drive Aberrant Signaling in MM

Repression of the microRNA miR-375 may be the primary mechanism underlying the constitutive activation of PDPK1/RPS6KA3 signaling in multiple myeloma.

Nivolumab Fails as Single-agent Treatment for Advanced Uterine Leiomyosarcoma

Nivolumab Fails as Single-agent Treatment for Advanced Uterine Leiomyosarcoma

Although nivolumab did not induce a response in any patients, the presence of tumor-associated macrophages may be a promising treatment avenue for novel combinations.

Pembrolizumab Effective Regardless of Prior Therapy in Classical Hodgkin Lymphoma

Pembrolizumab Effective Regardless of Prior Therapy in Classical Hodgkin Lymphoma

Pembrolizumab treatment resulted in high ORRs among patients with relapsed/refractory classic Hodgkin lymphoma regardless of previous therapy.

ASCO Releases Opinion on Hormonal Therapy for Castrate-resistant Prostate Cancer

ASCO Releases Opinion on Hormonal Therapy for Castrate-resistant Prostate Cancer

ASCO published a provisional clinical opinion regarding second-line hormonal therapy for men with non-metastatic or minimally symptomatic metastatic CRPC.

FDA Warns 14 Companies To Stop Selling Illegal Cancer Treatments

FDA Warns 14 Companies To Stop Selling Illegal Cancer Treatments

The US Food and Drug Administration has sent warning letters to 14 companies for illegally marketing more than 65 products that claim to diagnose, treat, or cure cancer.

TET2 Loss May Indirectly Cause Hematologic Oncogenesis

TET2 Loss May Indirectly Cause Hematologic Oncogenesis

TET2 loss may indirectly cause several hematologic malignancies, including myeloid, T cell, and B cell cancers.

Everolimus, Exemestane Safety Profile Same With Prior Chemo in Breast Cancer

Everolimus, Exemestane Safety Profile Same With Prior Chemo in Breast Cancer

Prior chemotherapy was associated with a trend of a greater rate of mortality, SAEs, and AEs causing treatment discontinuation, though these findings were not significant.

Lung Cancer: Timing May Affect EGFR mutation-related ctDNA Test Results

Lung Cancer: Timing May Affect EGFR mutation-related ctDNA Test Results

Timing might affect the results of an EGFR mutation-frequency circulating tumor DNA (ctDNA) test among patients with advanced NSCLC.

Adding Bevacizumab to Chemo May Prolong Survival in Recurrent Ovarian Cancer

Adding Bevacizumab to Chemo May Prolong Survival in Recurrent Ovarian Cancer

Adding bevacizumab to platinum-based chemotherapy may improve survival among women with recurrent ovarian cancer.

Lenalidomide Prolongs PFS Among Elderly Patients With DLBCL

Lenalidomide Prolongs PFS Among Elderly Patients With DLBCL

Data suggest that lenalidomide maintenance for 24 months can prolong PFS among elderly patients with DLBCL, but does not improve overall survival.

Cancer-specific Reference Values Established for PROMIS Domains

Cancer-specific Reference Values Established for PROMIS Domains

This study's information can inform policy issues, particularly the collection of patient-reported outcome data and its use in clinical practice.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters